MetaCap

Evogene Ltd (EVGN)

NASDAQ: EVGNIndustrialsAgricultural ChemicalsUSD

0.3162+0.0032 (+1.02%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

EVGN stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$1.55
52-week range
0.25 – 1.26
Day range
0.2891 – 0.341
Volume / Avg
62.77K / 1.40M
Beta
—

52-week range

$0.25$1.26

EVGN stock today

On Nov 20, EVGN ended the session at $0.3162, adding $0.0032 (1.02%), versus the S&P 500's 3.70% decline. Trading was light, with 62.77K shares changing hands, about 4% of the average daily volume. At this level, EVGN sits near the bottom of its 52-week range of $0.25 to $1.26: 74.9% below the high and 26.5% above the low.

Evogene has posted a net loss over the last twelve months (EPS of -$1.55), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Evogene

Company profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine.

Industry
Agricultural Chemicals
CEO
Mr. Ofer Haviv CPA
Headquarters
Rehovot
Employees
38

Financial highlights

Full financials

In fiscal 2025, Evogene generated $3.9 million in revenue, down 30.9% from fiscal 2024, its first annual decline since 2021. Evogene reported a net loss of $8.5 million, compared with a loss of $16.5 million a year earlier. Gross margin was -6.3% (down from 57.3%) and operating margin -364.2%.

Evogene annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$3.85M$5.58M$2.98M$1.68M$930.00K
Growth-30.91%+87.02%+78.03%+80.11%-10.58%
Net income$-8.48M$-16.48M$-23.88M$-26.64M$-27.79M
EPS (diluted)$1.08$-2.90$-5.20$-6.44$-0.69

Analyst forecast

Forecast

Consensus (1 analysts)

strong_buy

Avg. price target

$2.15+579.95%

  • Strong buy 0
  • Buy 1
  • Hold 0
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 19, 2026
EPS actual vs est.
$-0.17 vs $-0.19
Surprise
+10.53%

EVGN news

All EVGN news

Evogene peers

Industrials sector
EVGN peer companies
CompanyPrice% ChgMarket capCompare
SNESSenesTech Inc.0.69+6.15%$4.71Mvs EVGN
FRTTFort Technology Inc.0.47-9.79%$7.14Mvs EVGN
NXTSNexentis Technologies Inc.1.58-7.06%$1.05Mvs EVGN
BIOXBioceres Crop Solutions Corp.0.173-5.41%$11.04Mvs EVGN
ICLICL Group Ltd.4.08-1.45%—vs EVGN
UANCVR Partners LP95.09-0.88%—vs EVGN
AVDAmerican Vanguard Corporation0.68-1.48%$20.10Mvs EVGN
CBUSCibus Inc. Class A1.21-1.63%$92.73Mvs EVGN

Indexes, lists and sector

Evogene stock FAQ

What is Evogene's stock price today?

EVGN last traded at $0.3162 as of Nov 20, 4:00 PM EST, up 1.02% on the day. Prices are delayed at least 15 minutes.

Who is Evogene's CEO?

Mr. Ofer Haviv CPA is the chief executive officer of Evogene Ltd, which has about 38 employees.

What is the EVGN 52-week high?

The 52-week high for EVGN is $1.26 and the 52-week low is $0.25. The stock is currently 74.9% below its high.

Compare EVGN